Bladder Cancer New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Breast Cancer New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer Ulas D. Bayraktar, MD 2025-05-05
Mesothelioma New Indication: Lenvatinib with Pembrolizumab in Pleural Mesothelioma Ulas D. Bayraktar, MD 2023-11-20
Renal Cell Carcinoma New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Pembrolizumab for Early-Stage NSCLC Ulas D. Bayraktar, MD 2023-08-20
Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma Ulas D. Bayraktar, MD 2023-06-07
Cervical Cancer New Protocol: Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer Ulas D. Bayraktar, MD 2023-06-07
Biliary Tract Cancer New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-05-20
Uterine Cancer New Protocol: Pembrolizumab with Chemotherapy in Advanced Endometrial Cancer Ulas D. Bayraktar, MD 2023-04-14
Bladder Cancer New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer Ulas D. Bayraktar, MD 2023-04-14
